How Many Zafgen, Inc. (NASDAQ:ZFGN)’s Analysts Are Bearish?

January 11, 2018 - By Marie Mckinney

 How Many Zafgen, Inc. (NASDAQ:ZFGN)'s Analysts Are Bearish?

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc had 18 analyst reports since August 25, 2015 according to SRatingsIntel. On Thursday, January 21 the stock rating was upgraded by RBC Capital Markets to “Outperform”. Leerink Swann downgraded the stock to “Mkt Perform” rating in Thursday, December 3 report. On Thursday, March 10 the stock rating was downgraded by Canaccord Genuity to “Hold”. The stock of Zafgen, Inc. (NASDAQ:ZFGN) earned “Buy” rating by Cowen & Co on Tuesday, August 25. On Thursday, December 3 the stock rating was downgraded by Suntrust Robinson to “Neutral”. The stock has “Buy” rating by Canaccord Genuity on Friday, November 13. The stock has “Sector Perform” rating by RBC Capital Markets on Wednesday, December 2. The company was downgraded on Wednesday, July 20 by Cowen & Co. The firm earned “Mkt Perform” rating on Monday, October 19 by JMP Securities. The firm has “Outperform” rating by FBR Capital given on Thursday, January 21. Below is a list of Zafgen, Inc. (NASDAQ:ZFGN) latest ratings and price target changes.

05/01/2018 Broker: Cowen & Co Rating: Hold

The stock increased 1.26% or $0.07 during the last trading session, reaching $5.63. About 54,338 shares traded. Zafgen, Inc. (NASDAQ:ZFGN) has declined 36.39% since January 11, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company has market cap of $154.77 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. It currently has negative earnings.

More notable recent Zafgen, Inc. (NASDAQ:ZFGN) news were published by: which released: “Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph …” on October 10, 2017, also with their article: “Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 …” published on September 12, 2017, published: “Zafgen’s Second Act” on May 10, 2017. More interesting news about Zafgen, Inc. (NASDAQ:ZFGN) were released by: and their article: “Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)” published on October 12, 2017 as well as‘s news article titled: “Zafgen reports clinical progress and updates outlook for 2018” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.